Candida auris is a multidrug-resistant fungal pathogen that presents a serious threat to
global human health. Since the first reported case in 2009 in Japan, C. auris infections have …

Systemic fungal infections pose a serious clinical problem. Treatment options are limited,
and antifungal drug resistance is increasing. In addition, a substantial proportion of patients …

The epidemiology of invasive fungal infections (IFIs) in immunocompromised individuals has
changed over the last few decades, partially due to the increased use of antifungal agents to …

The cell wall is an essential component in fungal homeostasis. The lack of a covering wall in
human cells makes this component an attractive target for antifungal development. The host …

Candida albicans represents the most frequent isolated yeast from bloodstream infections.
Despite the remarkable progress in diagnostic and therapeutic approaches, these infections …

Breakthrough invasive fungal infections (IFI s) have emerged as a significant problem in
patients receiving systemic antifungals; however, consensus criteria for defining …

Candida species are the leading cause of invasive fungal infections worldwide and are
associated with acute mortality rates of~ 50%. Mortality rates are further augmented in the …

The emergence of new fungal pathogens makes the development of new antifungal drugs a
medical imperative that in recent years motivates the talents of numerous investigators …

Opportunistic fungal pathogens can cause a diverse range of diseases in humans. The
increasing rate of fungal infections caused by strains that are resistant to commonly used …

Fungal diseases cause millions of deaths per year worldwide. Antifungal resistance has
become a matter of great concern in public health. In recent years rates of non-albicans …